Next Generation Sequencing: Emerging Clinical Applications and Global Markets

NEW YORK, July 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Next Generation Sequencing: Emerging Clinical Applications and Global Markets

http://www.reportlinker.com/p01556799/Next-Generation-Sequencing-Emerging-Clinical-Applications-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

 

Highlights

 

The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 in 2013 and $7.6 billion in 2018 for a compound annual growth rate (CAGR) of 71.6%. The pre- and post-natal disease class as a segment was valued at $161.5 million in 2012. It is expected to reach $393.3 million in 2013 and nearly $2.1 billion in 2018, a CAGR of 39.4%. The cancer disease class as a segment was valued at $36.1 million in 2012. It is expected to reach $63.7 million in 2013 and nearly $2.5 billion in 2018, a CAGR of 108.3%.

 

STUDY GOALS AND OBJECTIVES

 

BCC Research's goal for this study is to provide an in-depth analysis of the clinical next generation sequencing (NGS) industry, an emerging industry with enormous market potential. The approach of analyzing the industry is taken in terms of workflow (e.g., sequencers, sequence capture, informatics) and key indications where NGS diagnostics will have market share by 2018. BCC Research examines the markets for NGS diagnostics for the years 2012, 2013 and 2018. The global NGS diagnostic markets are characterized and quantified by disease indication, test complexity, test purpose and geography. Market segments that provide exciting growth opportunities include cancer, rare genetic diseases and prenatal screening. The report provides a comprehensive discussion of NGS technologies, clinical applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts for clinical genetic testing.

 

REASONS FOR DOING THE STUDY

 

The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome. The HGP led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies). Beginning in 2005, the launch of next generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests. As a result, opportunities emerged in clinical applications that are currently reaching fruition. The NGS clinical market is still relatively young and emerging, yet it holds great commercial promise. Clinical value has been shown for many applications, and several launched tests are having good commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. Several molecular genetic tests that have been successful on non-NGS formats will run on NGS platforms in the future. At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential. These technical and market factors are driving this market so that in 2013, it is timely to examine the clinical segment of the sequencing industry.

 

CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE

 

This report fills a gap in the industry because its sole focus is on clinical applications run on next generation sequencing instruments. The industry is still emerging, so there is little information available regarding the applications for which NGS platforms will be used. The report provides a roadmap for understanding the ways in which next generation sequencing will be used in the diagnostic business during the next five years. It is a useful guide for strategic and business planning, as well as for learning about the impact new sequencing technologies will have in clinical diagnostics. This market report will be useful to many companies involved in the clinical, genetic testing and sequencing industries. It will be particularly valuable for companies in such industries as life science research tools, NGS instruments, molecular diagnostics, informatics clinical laboratories, pharmaceutical, biotechnology, microfluidics, lab-on-a-chip and sample preparation.

 

SCOPE AND FORMAT

 

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2012, 2013 and 2018. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the top research initiatives that are contributing to clinical NGS applications. Market driving forces are also discussed. The report examines the markets by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future. The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, common diseases, and pre- and post-natal screening. Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world. Market data covers the years 2012, 2013 and 2018. Industry sectors analyzed include NGS instruments, target enrichment, informatics, clinical laboratories and the prenatal screening industry. More than 110 companies in the clinical NGS industry are profiled in this report. BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2011 through 2013, including key alliance trends.

 

METHODOLOGY

 

Both primary and secondary research methodologies were used in preparing this study. BCC Research examined each of the key end-user market segments that will be commercially important during the next five years: cancer, rare genetic disorders, common disorders, and pre- and post-natal screening. Based on this analysis, the current and future applications of NGS technologies are evaluated in each of the major clinical market segments and sales revenues are forecast for 2013 through 2018. Based on analysis of both secondary and primary market sources, as well as the key trends in the industry, the report provides the current and projected market size for the various clinical NGS segments for the years 2012, 2013 and 2018.

 

 

 

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2

REASONS FOR DOING THE STUDY 2

CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE 3

SCOPE AND FORMAT 3

METHODOLOGY 4

INFORMATION SOURCES 4

RELATED BCC REPORTS 4

ANALYST CREDENTIALS 4

BCC ONLINE SERVICES 5

DISCLAIMER 5

CHAPTER 2 EXECUTIVE SUMMARY 7

EXECUTIVE SUMMARY 7

SUMMARY TABLE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE

CLASS, THROUGH 2018 ($ MILLIONS) 8

SUMMARY FIGURE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE

CLASS, 2012-2018 ($ MILLIONS) 8

CHAPTER 3 OVERVIEW 11

INTRODUCTION 11

TABLE 1 REPORT SCOPE 11

CLINICAL NEXT GENERATION SEQUENCING MARKETS 12

TABLE 2 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

DISEASE, THROUGH 2018 ($ MILLIONS) 12

CLINICAL NEXT GENERATION SEQUENCING GROWTH DRIVING FORCES 13

TECHNOLOGY DRIVERS 13

TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION

SEQUENCING 13

MARKET DRIVERS 14

TABLE 4 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES 15

CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS 15

TABLE 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS 16

CLINICAL NEXT GENERATION SEQUENCING INDUSTRY 16

TABLE 6 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY

PARTICIPANTS BY SECTOR 17

CHAPTER 4 TECHNOLOGIES 20

IMPORTANCE OF DNA 20

TABLE 7 DNA CHEMICAL BUILDING BLOCKS 20

TABLE 8 DNA TRANSLATION AND TRANSCRIPTION 20

TABLE 9 LONG-RANGE DNA STRUCTURE 21

GENETIC VARIATION AND ANALYSIS 22

TABLE 10 GENETIC VARIANT TYPES 22

GENETIC ANALYSIS TECHNOLOGIES 23

TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS BY COMPANY 23

NEXT GENERATION SEQUENCING IN CLINICAL APPLICATIONS 24

TABLE 12 GENETIC TESTING EVOLUTION 24

TABLE 13 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION

SEQUENCING DIAGNOSTICS 25

NEXT GENERATION SEQUENCING TECHNOLOGIES 26

HISTORY OF DNA SEQUENCING 26

TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2013 27

TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990–2013 32

TABLE 16 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST AND TIME TO

SEQUENCE A SINGLE HUMAN GENOME, 2001 AND 2013 ($) 33

SANGER SEQUENCING TECHNOLOGY 33

TABLE 17 SANGER SEQUENCING SUMMARY 33

TABLE 18 SANGER SEQUENCING IMPROVEMENTS 34

NEXT GENERATION SEQUENCING PLATFORMS 34

TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES 35

TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW 35

TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW 36

TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW 37

BENCHTOP SEQUENCERS 38

TABLE 23 BENCHTOP SEQUENCER PLATFORMS , 2010-2012 38

INFORMATICS TECHNOLOGIES 39

TABLE 24 NEXT GENERATION SEQUENCING BIOINFORMATICS WORKFLOW 39

BASE CALLING 40

MAPPING TO A REFERENCE SEQUENCE 40

TABLE 25 SEQUENCE ANNOTATION STEPS 41

VARIANT ANALYSIS 41

FUTURE TECHNOLOGY CHALLENGES 42

TABLE 26 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT GENERATION

SEQUENCING 42

TOP TEN CLINICAL NEXT GENERATION SEQUENCING INITIATIVES 43

TABLE 27 TOP 10 CLINICAL NEXT GENERATION SEQUENCING PROJECTS 43

1,000 GENOMES PROJECT 44

ARCHON X PRIZE IN GENOMICS 44

BASIC3 PROJECT 45

CANCER GENOME ATLAS 45

CANCER MOON SHOTS PROGRAM 46

CLARITY CHALLENGE 47

ENCODE PROJECT 47

GENOME IN A BOTTLE 47

MILLION VETERAN PROGRAM 48

NEUROMICS CONSORTIUM 48

CHAPTER 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS 50

INTRODUCTION 50

TABLE 28 CLINICAL NEXT GENERATION SEQUENCING NEAR- TO MID-TERM

APPLICATIONS 50

CANCER APPLICATIONS 51

TABLE 29 CANCER APPLICATIONS 51

MENDELIAN DISORDERS APPLICATIONS 53

TABLE 30 MENDELIAN DISORDERS APPLICATIONS 53

SCREENING APPLICATIONS 54

TABLE 31 SCREENING APPLICATIONS 54

TABLE 32 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN

SCREENING 57

INFECTIOUS DISEASE APPLICATIONS 57

TABLE 33 INFECTIOUS DISEASE APPLICATIONS 57

COMMON DISORDERS APPLICATIONS 59

TABLE 34 COMMON DISORDER APPLICATIONS 60

CHAPTER 6 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY 63

INTRODUCTION 63

TABLE 35 KEY SEGMENTS WITHIN THE NEXT GENERATION SEQUENCING CLINICAL

INDUSTRY 63

NEXT GENERATION SEQUENCING INSTRUMENT INDUSTRY 63

TABLE 36 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES:

COMMERCIAL PHASE 64

TABLE 37 NEXT GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET

SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 65

TABLE 38 NEXT GENERATION SEQUENCING HIGH-THROUGHPUT INSTRUMENT

COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 66

TABLE 39 NEXT GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR

MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 67

NEXT GENERATION SEQUENCING TARGET ENRICHMENT INDUSTRY 68

TABLE 40 NEXT GENERATION SEQUENCING-BASED TARGET ENRICHMENT

INDUSTRY 68

NEXT GENERATION SEQUENCING CLINICAL INFORMATICS INDUSTRY 69

TABLE 41 NEXT GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY

POSITIONING 70

CLINICAL LABORATORY INDUSTRY 71

TABLE 42 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS

LABORATORIES WITH NEXT GENERATION SEQUENCING DIAGNOSTICS 72

PRENATAL DIAGNOSTICS INDUSTRY 73

TABLE 43 NEXT GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS

INDUSTRY 74

TABLE 44 NORTH AMERICAN TEST COSTS AND PRICES ($) 75

TABLE 45 NEXT GENERATION SEQUENCING-BASED NON-INVASIVE PRENATAL

DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%) 76

TABLE 46 NON-INVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE

COMPETITORS 77

CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS AND

STRATEGIC ALLIANCES 78

ACQUISITIONS 78

TABLE 47 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS,

2011-2013 79

STRATEGIC ALLIANCES 81

TABLE 48 CLINICAL NEXT GENERATION SEQUENCING STRATEGIC ALLIANCES,

2011-2013 82

CHAPTER 7 NEXT GENERATION SEQUENCING DIAGNOSTICS MARKETS 92

GROWTH DRIVING FORCES 92

TABLE 49 CLINICAL NEXT GENERATION SEQUENCING KEY GROWTH DRIVING

FORCES, THROUGH 2018 92

GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET 93

TABLE 50 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

DISEASE, THROUGH 2018 ($ MILLIONS) 93

TABLE 51 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST

COMPLEXITY, THROUGH 2018 ($ MILLIONS) 95

TABLE 52 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST

PURPOSE, THROUGH 2018 ($ MILLIONS) 96

NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKETS 97

TABLE 53 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET

BY MARKET SEGMENT, THROUGH 2018 ($ MILLIONS) 97

TABLE 54 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET

BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 98

TABLE 55 GLOBAL CANCER NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET

BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 99

NEXT GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKETS 100

TABLE 56 GLOBAL NEXT GENERATION SEQUENCING CARDIOVASCULAR

DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 101

TABLE 57 GLOBAL NEXT GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC

MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 102

NEXT GENERATION SEQUENCING MENDELIAN DISORDERS DIAGNOSTIC

MARKETS 102

TABLE 58 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER

DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 103

TABLE 59 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER

DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 104

NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER

DIAGNOSTIC MARKETS 105

TABLE 60 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE

DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 105

TABLE 61 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE

DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($

MILLIONS)

106

NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKETS 106

TABLE 62 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC

MARKET FOR ALZHEIMER'S DISEASE BY TEST PURPOSE, THROUGH 2018 ($

MILLIONS)

107

TABLE 63 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC

MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 108

NEXT GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKETS 108

TABLE 64 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING

DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 109

TABLE 65 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING

DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 110

NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKETS 110

TABLE 66 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC

MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 111

TABLE 67 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC

MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 112

NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKETS 113

TABLE 68 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS

DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 113

TABLE 69 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS

DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 114

NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN TYPING

DIAGNOSTIC MARKETS 114

TABLE 70 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN

TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 115

TABLE 71 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN

TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 116

NEXT GENERATION SEQUENCING DIAGNOSTIC MARKETS BY GEOGRAPHY 116

TABLE 72 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

REGION, THROUGH 2018 ($ MILLIONS) 117

NORTH AMERICA 117

TABLE 73 NORTH AMERICAN NEXT GENERATION SEQUENCING DIAGNOSTIC

MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 117

EUROPE 118

TABLE 74 EUROPEAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

APPLICATION, THROUGH 2018 ($ MILLIONS) 118

CHINA 119

TABLE 75 CHINESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

APPLICATION, THROUGH 2018 ($ MILLIONS) 119

JAPAN 120

TABLE 76 JAPANESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

APPLICATION, THROUGH 2018 ($ MILLIONS) 120

REST OF WORLD 121

TABLE 77 REST OF WORLD NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET

BY APPLICATION, THROUGH 2018 ($ MILLIONS) 121

CHAPTER 8 PATENTS 123

CLINICAL NEXT GENERATION SEQUENCING PATENTS 123

TABLE 78 CLINICAL NEXT GENERATION SEQUENCING PATENTS, 2002-2012 123

CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION 123

TABLE 79 CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION,

2002-2012 123

CLINICAL NEXT GENERATION SEQUENCING PATENT ISSUES 124

POSSIBILITY OF WHOLE-GENOME SEQUENCING VIOLATING SINGLE-GENE

PATENTS 124

TABLE 80 COMPOSITION OF MATTER CLAIMS RELATING TO SINGLE-GENE PATENTS 125

STATUS OF SEQUENOM'S '054 PATENT LITIGATION 126

CHAPTER 9 COMPANY PROFILES 129

23ANDME INC. 129

TABLE 81 DATA NEEDS 129

ADAPTIVE BIOTECHNOLOGIES INC. 130

AGILENT TECHNOLOGIES INC. 131

ALMAC GROUP LTD. 132

AMBRY GENETICS 133

APPISTRY INC. 134

ARPEGGI INC. 134

ASTRID BIOSCIENCE GMBH 134

ASSURERX HEALTH 135

ASURAGEN INC. 135

BASE4INNOVATION LTD. 136

BECKMAN COULTER 136

BERRY GENOMICS CO. LTD. 137

BGI 138

BINA TECHNOLOGIES INC. 139

CARIS LIFE SCIENCES 140

CHRONIX BIOMEDICAL 140

CORIELL LIFE SCIENCES INC. 141

CORRELAGEN DIAGNOSTICS INC. 141

COUNSYL INC. 142

COURTAGEN LIFE SCIENCES INC. 142

CYPHER GENOMICS INC. 143

CYNVENIO BIOSYSTEMS INC. 143

DIOGENIX INC. 144

TABLE 82 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES 144

DNA ELECTRONICS LTD. 145

DNA LINK 145

DNANEXUS INC. 145

ELECTRONIC BIOSCIENCES 146

EUROFINS MWG OPERON 146

EXOSOME DIAGNOSTICS INC. 147

EXPRESSION ANALYSIS INC. 148

FOUNDATION MEDICINE 149

GATC BIOTECH AG 149

GE HEALTHCARE 150

GENAPSYS 151

GENDX BV 151

GENEDX INC. 152

GENIA TECHNOLOGIES INC. 153

TABLE 83 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 153

GENOLOGICS LIFE SCIENCES SOFTWARE 154

GENOMATIX SOFTWARE GMBH 154

GENOMEQUEST INC. 155

GENOMIC HEALTH INC. 156

GIGAGEN INC. 157

GNUBIO INC. 158

GOOD START GENETICS INC. 158

ILLUMINA INC. 159

INNOVATIONS EXCHANGE PTE LTD 161

INGENUITY SYSTEMS INC. 161

INVITAE 162

IREPERTOIRE 163

KAILOS GENETICS 163

KELLBENX INC. 163

KNOME INC. 164

LABORATORY CORPORATION OF AMERICA INC. 165

LABORATORY FOR MOLECULAR MEDICINE 165

LASERGEN INC. 166

LIFE TECHNOLOGIES INC. 166

LINGVITAE HOLDING AS 168

MACROGEN INC. 169

MAVERIX BIOMICS INC. 169

MD ANDERSON CANCER CENTER 170

MEDGENOME LABS PVT. LTD. 170

MEDOMICS LLC. 170

MULTIPLICOM NV 171

MYRIAD GENETICS INC. 172

NABSYS INC. 172

NATERA INC. 173

NEWGENE LTD. 173

NOBLEGEN BIOSCIENCES 174

NOVARTIS AG 174

OMICIA INC. 175

OMIXON BIOCOMPUTING KFT 176

ONCODNA SA 176

OXFORD GENE TECHNOLOGY 177

OXFORD NANOPORE TECHNOLOGIES 177

PACIFIC BIOSCIENCES OF CALIFORNIA INC. 178

PARABASE GENOMICS 180

PATHOGENICA 180

PATHOGENETIX 181

PERKIN ELMER INC. 182

PERSONAL GENOME DIAGNOSTICS INC. 184

PERSONALIS INC. 184

PICOSEQ 185

POPULATION GENETICS TECHNOLOGIES LTD. 185

PORTABLE GENOMICS LLC 187

PREVENTIONGENETICS INC. 187

QIAGEN 188

QUANTUMDX 189

RAINDANCE TECHNOLOGIES INC. 190

REAL TIME GENOMICS INC. 191

RESPONSE GENETICS INC. 191

ROCHE HOLDING AG 191

SCIGENOM LABS 193

SENGENICS INTERNATIONAL PTE LTD. 194

SEQUENOM INC. 194

SEQUENTA INC. 195

SEQUOIA GENETICS CO. LTD. 196

SEVEN BRIDGES GENOMICS INC. 196

SIEMENS AG 197

SILICON VALLEY BIOSYSTEMS 198

SISTEMAS GENOMICOS 198

SOFTGENETICS LLC 199

STATION X INC. 199

STRAND LIFE SCIENCES 199

STRATOS GENOMICS INC. 200

SUNDANCE DIAGNOSTICS INC. 200

SYAPSE 201

THERMO FISHER SCIENTIFIC, INC. 201

TRANSGENOMIC INC. 202

TROVAGENE INC. 202

WARP DRIVE BIO LLC 203

YIKON GENOMICS CO. LTD. 203

ZS GENETICS 204

 

LIST OF TABLES

 

SUMMARY TABLE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE

CLASS, THROUGH 2018 ($ MILLIONS) 8

TABLE 1 REPORT SCOPE 11

TABLE 2 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

DISEASE, THROUGH 2018 ($ MILLIONS) 12

TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING 13

TABLE 4 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES 15

TABLE 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS 16

TABLE 6 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY

PARTICIPANTS BY SECTOR 17

TABLE 7 DNA CHEMICAL BUILDING BLOCKS 20

TABLE 8 DNA TRANSLATION AND TRANSCRIPTION 20

TABLE 9 LONG-RANGE DNA STRUCTURE 21

TABLE 10 GENETIC VARIANT TYPES 22

TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS BY COMPANY 23

TABLE 12 GENETIC TESTING EVOLUTION 24

TABLE 13 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION

SEQUENCING DIAGNOSTICS 25

TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2013 27

TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990–2013 32

TABLE 16 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST AND TIME TO

SEQUENCE A SINGLE HUMAN GENOME, 2001 AND 2013 ($) 33

TABLE 17 SANGER SEQUENCING SUMMARY 33

TABLE 18 SANGER SEQUENCING IMPROVEMENTS 34

TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES 35

TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW 35

TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW 36

TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW 37

TABLE 23 BENCHTOP SEQUENCER PLATFORMS , 2010-2012 38

TABLE 24 NEXT GENERATION SEQUENCING BIOINFORMATICS WORKFLOW 39

TABLE 25 SEQUENCE ANNOTATION STEPS 41

TABLE 26 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT GENERATION

SEQUENCING 42

TABLE 27 TOP 10 CLINICAL NEXT GENERATION SEQUENCING PROJECTS 43

TABLE 28 CLINICAL NEXT GENERATION SEQUENCING NEAR- TO MID-TERM

APPLICATIONS 50

TABLE 29 CANCER APPLICATIONS 51

TABLE 30 MENDELIAN DISORDERS APPLICATIONS 53

TABLE 31 SCREENING APPLICATIONS 54

TABLE 32 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN

SCREENING 57

TABLE 33 INFECTIOUS DISEASE APPLICATIONS 57

TABLE 34 COMMON DISORDER APPLICATIONS 60

TABLE 35 KEY SEGMENTS WITHIN THE NEXT GENERATION SEQUENCING CLINICAL

INDUSTRY 63

TABLE 36 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL

PHASE 64

TABLE 37 NEXT GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET

SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 65

TABLE 38 NEXT GENERATION SEQUENCING HIGH-THROUGHPUT INSTRUMENT

COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 66

TABLE 39 NEXT GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR

MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 67

TABLE 40 NEXT GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY 68

TABLE 41 NEXT GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY

POSITIONING 70

TABLE 42 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS

LABORATORIES WITH NEXT GENERATION SEQUENCING DIAGNOSTICS 72

TABLE 43 NEXT GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS

INDUSTRY 74

TABLE 44 NORTH AMERICAN TEST COSTS AND PRICES ($) 75

TABLE 45 NEXT GENERATION SEQUENCING-BASED NON-INVASIVE PRENATAL

DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%) 76

TABLE 46 NON-INVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE

COMPETITORS 77

TABLE 47 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS,

2011-2013 79

TABLE 48 CLINICAL NEXT GENERATION SEQUENCING STRATEGIC ALLIANCES,

2011-2013 82

TABLE 49 CLINICAL NEXT GENERATION SEQUENCING KEY GROWTH DRIVING

FORCES, THROUGH 2018 92

TABLE 50 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

DISEASE, THROUGH 2018 ($ MILLIONS) 93

TABLE 51 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST

COMPLEXITY, THROUGH 2018 ($ MILLIONS) 95

TABLE 52 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST

PURPOSE, THROUGH 2018 ($ MILLIONS) 96

TABLE 53 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET

BY MARKET SEGMENT, THROUGH 2018 ($ MILLIONS) 97

TABLE 54 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET

BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 98

TABLE 55 GLOBAL CANCER NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET

BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 99

TABLE 56 GLOBAL NEXT GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC

MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 101

TABLE 57 GLOBAL NEXT GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC

MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 102

TABLE 58 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER

DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 103

TABLE 59 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER

DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 104

TABLE 60 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE

DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 105

TABLE 61 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE

DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 106

TABLE 62 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC

MARKET FOR ALZHEIMER'S DISEASE BY TEST PURPOSE, THROUGH 2018 ($

MILLIONS)

107

TABLE 63 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC

MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 108

TABLE 64 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING

DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 109

TABLE 65 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING

DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 110

TABLE 66 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC

MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 111

TABLE 67 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC

MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 112

TABLE 68 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS

DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 113

TABLE 69 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS

DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 114

TABLE 70 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN

TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 ($ MILLIONS) 115

TABLE 71 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN

TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 ($ MILLIONS) 116

TABLE 72 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

REGION, THROUGH 2018 ($ MILLIONS) 117

TABLE 73 NORTH AMERICAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET

BY APPLICATION, THROUGH 2018 ($ MILLIONS) 117

TABLE 74 EUROPEAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

APPLICATION, THROUGH 2018 ($ MILLIONS) 118

TABLE 75 CHINESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

APPLICATION, THROUGH 2018 ($ MILLIONS) 119

TABLE 76 JAPANESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY

APPLICATION, THROUGH 2018 ($ MILLIONS) 120

TABLE 77 REST OF WORLD NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET

BY APPLICATION, THROUGH 2018 ($ MILLIONS) 121

TABLE 78 CLINICAL NEXT GENERATION SEQUENCING PATENTS, 2002-2012 123

TABLE 79 CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION,

2002-2012 123

TABLE 80 COMPOSITION OF MATTER CLAIMS RELATING TO SINGLE-GENE PATENTS 125

TABLE 81 DATA NEEDS 129

TABLE 82 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES 144

TABLE 83 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 153

BIO126A - Next Generation Sequencing: Emerging Clinical Applications and Global Markets

SUMMARY FIGURE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE

CLASS, 2012-2018 ($ MILLIONS)

 

 

 

To order this report:

Genomics Industry: Next Generation Sequencing: Emerging Clinical Applications and Global Markets

 

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.